Eevia Health (EEVIA) Status Update summary

Strategic focus and business model shift

• Accelerated shift from raw material-derived products to science-backed, condition-specific health solutions, especially in gut health, with a focus on substantiated health claims and clinical data.

• Divestment strategy to streamline operations, including splitting off wood-based and berry manufacturing assets into new entities, aiming for non-dilutive funding and operational focus.

• Emphasis on branded, proprietary products targeting specific health issues, leveraging Arctic polyphenols and scientific partnerships.

Product development and innovation

• Development of gut health products using Proanthocyanidins from crowberry and lingonberry, aiming to restore gut lining integrity and modulate the microbiome.

• Collaboration with leading academic experts in gut and kidney health to support product efficacy and credibility.

• Retinari, a nutraceutical for age-related macular degeneration, shows promising preclinical results in reversing vision loss in animal models.

Market approach and revenue strategy

• Refined distribution strategy focusing on practitioner and cutting-edge consumer brands, leveraging existing networks in Europe, North America, and Australasia.

• Past over-reliance on a single customer led to revenue volatility; new strategy aims to diversify customer base and stabilize growth.

• Targeting EUR 3 million in revenue for next year, with a focus on improving gross margin and returning to profitability.